Document and Entity Information - USD ($)

12 Months Ended

Apr. 30, 2022

Jul. 02, 2022

Oct. 31, 2021

Cover [Abstract]

Document Type

10-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2022

Document Fiscal Year Focus

2022

Document Fiscal Period Focus

FY

Trading Symbol

KALV

Entity Registrant Name

KALVISTA PHARMACEUTICALS, INC.

Entity Central Index Key

0001348911

Current Fiscal Year End Date

--04-30

Entity Well-known Seasoned Issuer

No

Entity Filer Category

Non-accelerated Filer

Entity Small Business

true

Entity Emerging Growth Company

false

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Voluntary Filers

No

Entity Shell Company

false

Document Annual Report

true

Title of 12(b) Security

Common Stock, $0.001 par value per share

Security Exchange Name

NASDAQ

Document Transition Report

false

Entity File Number

001-36830

Entity Incorporation, State or Country Code

DE

Entity Tax Identification Number

20-0915291

Entity Address, Address Line One

55 Cambridge Parkway

Entity Address, Address Line Two

Suite 901 East

Entity Address, City or Town

Cambridge

Entity Address, State or Province

MA

Entity Address, Postal Zip Code

02142

City Area Code

857

Local Phone Number

999-0075

Entity Common Stock, Shares Outstanding

24,570,872

Entity Public Float

$ 378,647,652

ICFR Auditor Attestation Flag

false

Documents Incorporated by Reference

Information required in responses to Part III of Form 10-K is hereby incorporated by reference to portions of the Registrant’s Proxy Statement for the Annual Meeting of Stockholders to be held in 2022. The Proxy Statement will be filed by the Registrant with the Securities and Exchange Commission no later than 120 days after the end of the Registrant’s fiscal year ended April 30, 2022.

Auditor Firm ID

34

Auditor Name

Deloitte & Touche LLP

Auditor Location

Boston, Massachusetts